The use of axicabtagene ciloleucel, the other FDA-approved CD19-specific CAR-T, resulted in 52% patients with relapsed or refractory DLBCL achieving CR in a multicenter clinical trial (ZUMA-1) [4]. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.